Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells

Manuela Mancini(Istituto Oncologico Romagnolo), Simona Soverini(University of Bologna)

Cancers

January 31, 2022

10.3390/cancers14030738

Cited by 2

Related Papers

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

|Blood|2011|460

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

|Cancer Cell|2014|366

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

|Cancer|2013|143

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis

|Leukemia|2017|38

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted

|Biomarker Research|2023|6